<DOC>
	<DOCNO>NCT02444585</DOCNO>
	<brief_summary>The overall objective propose study quantify bone loss around non-cemented total hip replacement femoral acetabular component use DEXA analysis patient receive Prolia ( denosumab ) first year follow total hip joint replacement surgery , compare bone loss control hip replacement patient receive placebo . The primary outcome variable difference loss bone mineral density experimental group take denosumab placebo control group , calculate percentage , Gruen Zone 7 , proximal medial calcar region femur , follow-up period 12 post-operative month . The secondary objective assess follow variable : - Bone turnover difference experimental group take denosumab placebo control group , utilize serum C-terminal cross-linking telopeptides type I collagen ( CTX-I ) ( bone resorption ) N-terminal propeptides type I procollagen ( P1NP ) ( bone formation ) . - Difference loss bone mineral density experimental group take denosumab placebo control group , calculate percentage , Gruen Zones 1 6 , periprosthetic femur . - Difference loss bone mineral density experimental group take denosumab placebo control group , calculate percentage , DeLee Charnley 's Zones 1 3 , periprosthetic acetabulum . Exploratory objectives assess difference loss bone mineral density contralateral , non-operated femur experimental control group , determine role covariates weight , gender , age , baseline BMD , implant type percent change BMD 12 month .</brief_summary>
	<brief_title>Longjohn Amgen Study - Effect Denosumab ...</brief_title>
	<detailed_description>EXPERIMENTAL PLAN Study Design The propose study Phase 3 , double-blinded , randomize control study . All 80 patient , placebo denosumab group , adhere protocol . Patient screen perform orthopaedic surgeon ( Donald Longjohn , MD Daniel Oakes , MD ) preoperative clinical appointment , base Inclusion Exclusion Criteria . If patient deem appropriate study , consent participation propose study obtain prior hip replacement surgery . Two dos denosumab give , 60 mg . Study Day 1 define day injection , first 60 mg dose denosumab placebo administer within 7-14 day follow hip replacement surgery . The second injection ( 60 mg ) either denosumab placebo administer 6 month Study Visit # 1 . DEXA perform treat femur use 7 Gruen radiographic zone interest , contralateral femur , use traditional analysis protocol , well acetabulum treat side use 3 zones interest . This perform ( 1 ) Study Visit # 1 , date first injection ; ( 2 ) 3 month injection ; ( 3 ) 6 month injection , immediately prior injection # 2 ; ( 4 ) 12 month Study Visit # 1 . Bone mineral density patient assess utilizing Hologic Bone Densitometer software metal subtraction treat femur . As well , bone turnover marker determine base line blood drawn : ( 1 ) Study Visit # 1 , date first injection ; ( 2 ) 1 month injection ; ( 3 ) 3 month injection ; ( 4 ) 6 month injection 1 , date injection 2 ; ( 5 ) 12 month injection # 1 ( 6 month injection 2 ) . Number Centers ( 1 ) - Orthopaedic Institute Children ( Orthopaedic Hospital ) , 403 W. Adams Boulevard , Los Angeles , CA Number Subjects Number Subjects = 80 Estimated Study Duration Twenty four ( 24 ) month . The study duration individual participant twelve ( 12 ) month : Enrollment take place course first 12 month study patient follow 12 month follow joint replacement surgery , total duration 24 month . If study enrollment complete end first 12 month , enrollment period extend additional 6 month . SUBJECT ELIGIBILITY Inclusion Criteria Inclusion criterion allocate patient undergo elective total hip replacement due osteoarthritis . The prosthetic device standard , non-cemented taper total hip replacement , Alloclassic® ( Zimmer , Inc. , Warsaw , IN ) similarly shape implant material ( titanium alloy ) Summit Hip ( Depuy , Inc. , Warsaw , IN ) . Subjects 55 75 year age . Both gender include . Prior surgery , creatinine clearance , calcium , vitamin D check . Creatinine clearance rate must 30 ml/min , vitamin D serum level must great 12 ng/ml , patient hypocalcemic . If vitamin D serum level normal ( 30ng/ml ) 1000 mg calcium least 1000 Units vitamin D , recommend surgeon time operation likely sufficient correct problem . Exclusion Criteria Current use medication may affect bone mineral metabolism ( e.g. , glucocorticoid , diuretic , estrogen , oral contraceptive , tamoxifen , bisphosphonates , raloxifene , calcitonin , PTH , anticonvulsant , immunosuppressant ) , subject history disease affect bone mineral metabolism ( e.g. , thyrotoxicosis , hyperparathyroidism , hypocalcemia hypoparathyroidism , chronic renal failure , Cushing 's disease , rheumatoid arthritis , hematological disease , alcohol abuse &gt; 3 drink day ) , cancer . Additionally , patient take immunosuppressant exclude . Patients treat anti-TNF past 3 month exclude . Patients hypocalcemia patient use bisphosphonates 2-3 year prior surgery exclude . Additionally , patient creatinine clearance rate 30 ml/minwill exclude , patient severe vitamin D deficiency ( &lt; 12 ng/ml ) . Patients decrease hepatic function measure AST , ALT , Alkaline Phosphatase Total Bilirubin exclude study . Patients solid organ bone marrow transplant exclude . Patients history malignancy within past 5 year , exception basal cell carcinoma cervical carcinoma situ , exclude . Additionally , incidence serious infection may higher patient treated denosumab , patient poorly control diabetes/HbA1C exclude . SUBJECT ENROLLMENT AND TREATMENT ASSIGNMENT A total 80 subject ( N=80 ) enrol first twelve month propose study . 40 patient randomly receive placebo treatment , 40 receive denosumab treatment . All individual interact patient , include operate surgeon patient , blind , exception Orthopaedic Hospital pharmacist un-blinded . The pharmacist charge receive maintain drug time administer patient . TREATMENT PROCEDURES Amgen Investigational Product Denosumab Dosage , Administration , Schedule On postoperative day 7-14 ( Study Visit # 1 ) , 6 month follow Study Visit # 1 ( date first injection , DEXA , blood draw ) , patient receive either 60 mg denosumab placebo . Dose Escalation Stopping Rules There dose escalation . Therapy evaluate subject develops symptomatic hypocalcemia , serious skin infection , osteonecrosis jaw , pancreatitis . The subject advise seek prompt medical attention develop sign symptom . If Adverse Events develop define section 9.1. , suspicion may relate drug , case ( ) investigate , deem necessary , patient doctor may un-blinded purpose treatment . If symptom develop Study Visit # 6 ( date second final injection ) , even un-blinding occurs treatment purpose , patient ask come back final Study Visit ( # 5 ) 12 month DEXA blood draw , willing . If serious side effect occur prior second injection ( Study Visit # 4 ) , patient may receive second injection serious medical concern . Dosage Adjustments There dose adjustment . Concomitant Therapy Subjects instruct take 1000 mg calcium least 1000 Units vitamin D per day . Prescribed Therapy Study Period No use medication list exclusion criterion . Other Treatment Procedures None</detailed_description>
	<mesh_term>Denosumab</mesh_term>
	<criteria>Inclusion criterion allocate patient undergo elective total hip replacement due osteoarthritis . The prosthetic device standard , noncemented taper total hip replacement , Alloclassic® ( Zimmer , Inc. , Warsaw , IN ) similarly shape implant material ( titanium alloy ) Summit Hip ( Depuy , Inc. , Warsaw , IN ) . Subjects 55 75 year age . Both gender include . Prior surgery , creatinine clearance , calcium , vitamin D check . Creatinine clearance rate must 30 ml/min , vitamin D serum level must great 12 ng/ml , patient hypocalcemic . If vitamin D serum level normal ( 30ng/ml ) 1000 mg calcium least 1000 Units vitamin D , recommend surgeon time operation likely sufficient correct problem . Current use medication may affect bone mineral metabolism ( e.g. , glucocorticoid , diuretic , estrogen , oral contraceptive , tamoxifen , bisphosphonates , raloxifene , calcitonin , PTH , anticonvulsant , immunosuppressant ) , subject history disease affect bone mineral metabolism ( e.g. , thyrotoxicosis , hyperparathyroidism , hypocalcemia hypoparathyroidism , chronic renal failure , Cushing 's disease , rheumatoid arthritis , hematological disease , alcohol abuse &gt; 3 drink day ) , cancer . Additionally , patient take immunosuppressant exclude . Patients treat antiTNF past 3 month exclude . Patients hypocalcemia patient use bisphosphonates 23 year prior surgery exclude . Additionally , patient creatinine clearance rate 30 ml/minwill exclude , patient severe vitamin D deficiency ( &lt; 12 ng/ml ) . Patients decrease hepatic function measure AST , ALT , Alkaline Phosphatase Total Bilirubin exclude study . Patients solid organ bone marrow transplant exclude . Patients history malignancy within past 5 year , exception basal cell carcinoma cervical carcinoma situ , exclude . Additionally , incidence serious infection may higher patient treated denosumab , patient poorly control diabetes/HbA1C exclude .</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>